Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of ACT-541478 in healthy subjects
NCT04452006Phase 1Terminated
- Sponsor
- Idorsia
- Start
- Jul 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of daridorexant in Central nervous system diseases (10 arms), sponsored by Idorsia. Primary endpoint: Treatment-emergent (serious) Adverse Events up to 5 days. Started Jul 2020; status: terminated.
02
Drugs
daridorexant
03
Conditions
Central nervous system diseases
Beyond the preview
Go deeper on NCT04452006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04452006.